Letrozole is an aromatase inhibitor that has an unapproved use for ovulation induction with infertility. Because of the proximity of this use to conception, we selected letrozole to study the effect of 3 different methods for identifying the pregnancy start date and their impact on exposure misclassification. Using electronic health data from the US Sentinel database (2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015), we identified live-birth pregnancies conceived through in-vitro fertilization or intrauterine insemination. The pregnancy start was calculated using 1) a validated algorithm to estimate the last menstrual period (LMP), 2) LMP + 14 days (i.e., conception estimate), and 3) the fertility-procedure date. We identified 47,628 live-births after intrauterine insemination (n = 24,962) and in-vitro fertilization (n = 22,666), in which 2,458 (5.3%) mothers received letrozole. The algorithm-based conception estimate occurred within 14 days of the fertility procedure for 78.3% of pregnancies. Defining pregnancy start as LMP (45.7/1,000 pregnancies) or LMP + 14 days (12.7/1,000 pregnancies) overestimated letrozole exposure during pregnancy by 8.4-fold and 2.3-fold, respectively, compared with defining it at the date of the fertility procedure (5.5/1,000 pregnancies). While most studies of drug utilization in pregnancy use LMP as the conventional pregnancy start, this introduced substantial exposure misclassification in the example of letrozole. LMP + 14 days was less biased. Researchers should carefully consider the impact of the method for identifying the pregnancy start date on the potential for exposure misclassification. drug utilization; exposure misclassification; letrozole; pregnancy Abbreviations: IUI, intrauterine insemination; IVF, in-vitro fertilization; LMP, last menstrual period.
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Letrozole (Femara; Novartis Pharmaceuticals, East Hanover, New Jersey) is an aromatase inhibitor used in hormone receptor-positive and locally advanced postmenopausal breast cancer. This product also has an off-label use (not included in the indications approved by the US Food and Drug Administration) for ovulation induction in infertility as a lower-cost alternative to gonadotropins (1) . It is administered on days 3-7 of the menstrual cycle to suppress ovarian estradiol secretion and facilitate ovulation. Higher ovulation and live-birth rates have been observed with letrozole compared with clomiphene citrate among women with polycystic ovary syndrome (2, 3) .
When administered during pregnancy in animal studies, letrozole was shown to have embryo-fetal toxicities, increasing risk for intrauterine mortality and teratogenesis (4) . Postmarketing reports have identified numerous exposures to letrozole during pregnancy that were associated with spontaneous abortions and congenital birth defects (5). Additionally, letrozole has been studied for early pregnancy termination (6) . One study with limited data suggests that letrozole use prior to conception for ovulation stimulation does not result in an increased risk for adverse pregnancy outcomes (7) . However, there is concern about accidental postconception exposure after failure to recognize the start of pregnancy.
The close temporality of letrozole use to the pregnancy start date positions it well as a methodological example to study the effect of imperfect estimation in the pregnancy start date on misclassification of first-trimester exposure in claims-based observational studies. Most drug utilization studies in pregnant women use a validated algorithm to estimate the pregnancy start as the date of the last menstrual period (LMP). However, from a teratogenic perspective, exposures prior to conception (LMP + 14 days) are generally not of concern unless extended half-lives result in exposure beyond the conception date.
Our study sought to identify a population of women conceiving through in-vitro fertilization (IVF) or intrauterine insemination (IUI), where the date of the fertility procedure represents the timing after which an exposure during pregnancy would be of concern. We aimed to quantify the presence of misclassification of first-trimester letrozole exposure when using a previously validated algorithm to identify the pregnancy start date as either the LMP or as the estimated date of conception (LMP + 14 days) when compared with the date of a fertility procedure.
METHODS

Data source
The US Food and Drug Administration's Sentinel System provides active surveillance of health-care data from multiple sources to monitor the safety of regulated medical products (8) . Data partners include public, private, and integrated care networks but are composed mostly of commercially insured individuals. Each of 15 data partners participating in this study contributed medical and pharmacy data, including inpatient and outpatient diagnoses and procedures as well as outpatient pharmacy dispensing records. Data are formatted using a common data model that allows for standardized queries across data partners and includes a robust data quality-assurance process.
Live-birth pregnancies after IVF and IUI procedures
We identified live-birth pregnancies among women aged 10-54 years at delivery using a validated algorithm based on International Classification of Diseases, Ninth Revision, Clinical Modification, diagnosis and procedure codes (9) . Pregnancies between January 2001 and September 2015 were identified. Eligible pregnancies required continuous health-plan enrollment with medical and pharmacy benefits for a minimum 384 days (42 weeks + 90 days) prior to delivery admission. We further restricted our cohort to pregnancies with procedures for IUI or IVF, selecting the closest procedure to the live-birth delivery. Included coding was limited to insemination procedures for IUI and embryo transfer for IVF, the dates of which represent the date after which a teratogenic exposure during pregnancy would be of concern ( Table 1) .
The start of pregnancy was obtained using 3 distinct methodologies. First, we used the fertility procedure closest to delivery as the date after which an exposure during pregnancy would be of concern. We refer to this date as the "fertility procedurebased pregnancy start date." Second, we used a previously validated claims-based algorithm to estimate the start of pregnancy using diagnosis codes to determine the LMP date (9) . The algorithm imposes a 273-day gestational age for deliveries without a preterm or postterm birth diagnosis, a 245-day gestational age for preterm births with an unspecified gestational age, and the upper limit of gestational age for live-births with a specified age range at birth (e.g., assumes gestational age of 32 weeks for code 765.26, "31 or 32 weeks gestation"). We refer to this date as the "LMP-based pregnancy start date," and it is the most commonly used method to identify teratogenic exposures for drug utilization research. Third, we used the same algorithm but estimated pregnancy start as LMP + 14 days as an estimate of conception. We refer to this date as the "conception-based pregnancy start date." See Figure 1 for a depiction of pregnancy start dates.
Letrozole use for ovulation stimulation
We identified letrozole use starting 4 weeks prior to each estimated pregnancy start date as a relevant exposure intended for ovulation induction in the current cycle. Only the final letrozole dispensing prior to delivery was analyzed, because this was the most proximal exposure to the pregnancy. The indication for use was characterized as ovulation induction if the prescription was written for a 5-day supply or with a maximum of 15 tablets dispensed (3 tablets daily for 5 days). The exposure was indexed on the 5th day after dispensing as the final day of exposure for the treatment regimen. Our definition effectively excluded off-label letrozole use for premenopausal breast cancer; that therapy is intended to be long-term, and prescriptions are rarely dispensed for less than a 30-day supply.
Statistical analysis
We first applied both the fertility procedure-based and LMPbased pregnancy start dates for all women conceiving through a fertility procedure. The distribution of the LMP-based start date was depicted surrounding the fertility procedure-based start date as the reference standard to quantify misclassification of the pregnancy start date when using traditional estimates of gestational age ( Figure 2 ). Next, we calculated the distribution of letrozole exposures surrounding the fertility procedure-based, LMP-based, and conception-based pregnancy start dates among women having fertility procedures. The distributions are presented graphically in Figure 3 . Rates of first-trimester exposure per 1,000 pregnancies using both algorithm-based pregnancy start dates (LMP and LMP + 14 days) were contrasted with the rate of exposure using the fertility procedure-based pregnancy start date as reference. The ratio of these rates was used to quantify the impact of exposure misclassification.
Finally, we used a simulated data set to illustrate the impact of exposure misclassification on estimates of relative risk in a study to assess risk for congenital malformations after letrozole exposure during pregnancy ( Figure 4 ). Exposure misclassification was generated by assigning a fraction of unexposed to exposed. This misclassification was assumed to be equal (i.e., nondifferential) between those with and without congenital malformations. The impact of exposure misclassification on the relative risk is depicted, varying both the true relative risk (set as 3.0, 2.5, 2.0, and 1.5) and the proportion of misclassification in the exposed cases (varied from 0% to 90%). Here, the proportion of misclassification in the exposed cases was calculated as the number of true pregnancy exposures to letrozole divided by the total number of letrozole exposures identified within a study to assess risk for congenital malformations. All analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina), and R, version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria), with each data partner running a standardized distributed analytical program. This study was not under purview of institutional review boards because the Sentinel System is considered a public health surveillance activity (10) .
RESULTS
We identified 47,628 women with a live-birth pregnancy after an IUI (n = 24,962) or IVF (n = 22,666) procedure (Table 2) . Of all pregnancies, 16.4% resulted in a preterm birth, and 13.6% resulted in a postterm birth. Letrozole was more frequently used in the 4 weeks prior to ovulation induction for IUI (n = 2,436, 10.75%) than in the 4 weeks prior to embryo transfer for IVF (n = 112, 0.45%). A depiction of the timing of IUI and IVF procedures and the implementation of our pregnancy start dates is shown in Figure 1 .
In our study, women conceiving through fertility procedures had a median time from conception through delivery (i.e., pregnancy length) of 257 days (interquartile range, 245-265). This was consistent with the algorithm-derived pregnancy length of 259 days with our conception-based pregnancy start date for women without preterm or postterm birth coding (i.e., 273 days − 14 days = 259 days). Conversely, the LMP-based pregnancy start date overestimated pregnancy length among women with fertility procedures by a median of 16 days (interquartile No. of Pregnancies Figure 3 . Distribution of letrozole use for ovulation induction surrounding 3 methods to estimate pregnancy start, among live-birth pregnancies that resulted from fertility procedures, Sentinel database, United States, 2001-2015. Vertical dashed line represents start of pregnancy. Pregnancy start and gestational week were calculated using 3 methods: A) the fertility procedure-based pregnancy start date, defined as the date of the closest fertility procedure to the livebirth delivery; B) the conception-based pregnancy start date, calculated using an algorithm to estimate the date of the last menstrual period (LMP) and adding 14 days; and C) the LMP-based pregnancy start date. Exposures were assessed from 4 weeks prior to the estimated pregnancy start date until delivery and were indexed on fifth day after dispensing. . Exposure misclassification was generated by assigning a fraction of unexposed to exposed, with equal misclassification percentage to cases (those with congenital malformation) and controls (those without congenital malformation). We varied true RRs and the proportion misclassified among exposed cases. The estimated relative risk (RR′) can be expressed as a function of the true relative risk (RR) and the proportion of exposed cases misclassified (p mis ), as the following:
Proportion Misclassified Among Exposed
Estimated RRs are diluted with increasing levels of exposure misclassification and the dilution effect takes place faster and is more pronounced with higher true RR.
range, 11-23). The distribution of the LMP-based pregnancy start date, relative to the procedure-based start date as reference, is shown in Figure 2 for all women with a fertility procedure. When using the procedure-based pregnancy start date, letrozole had a peak distribution between 1 and 2 weeks prior to the fertility procedure, with 90.7% (n = 2,548) of all prescriptions having a final day of supply in the 4 weeks prior to the pregnancy start date ( Figure 3A) . Of the 9.3% (n = 260) of women with their final letrozole prescription after their procedure-based pregnancy start date, 65% (n = 169) had a final day of supply during weeks 3-4 after their final fertility procedure (the timing for ovulation at the next cycle).
Use of the conception-based pregnancy start date similarly yielded the greatest distribution of letrozole exposure 1-2 weeks prior to the start of pregnancy, although with a more subdued peak and a greater extent of dispersion ( Figure 3B ). This methodology resulted in a total of 604 (22.1%) letrozole exposures observed during pregnancy. The conception-based pregnancy start date (12.7/1,000 pregnancies) yielded a 2.3-fold overestimation of letrozole exposure during pregnancy compared with the fertility procedure-based pregnancy start date (5.5/1,000 pregnancies).
The distribution of letrozole exposures using the LMP-based pregnancy start date had a peak distribution during weeks 1-2 of pregnancy ( Figure 3C ). Only 29.6% (n = 914) of letrozole prescriptions with the LMP-based pregnancy start date were identified in the 4 weeks prior to the fertility procedure, with an estimated 70.4% (n = 2,176) of all letrozole exposures during pregnancy. This represents an 8.4-fold overestimation in the rate of pregnancy exposure with the LMP-based (45.7/1,000 pregnancies) compared with the procedure-based pregnancy start date (5.5/1,000 pregnancies).
Our simulated example shows the effect of exposure misclassification on estimates of relative risk for congenital malformations. Figure 4 shows that estimated relative risks are diluted with increasing levels of exposure misclassification, and the dilution effect takes place faster and is more pronounced with higher true relative risk. Abbreviations: IUI, intrauterine insemination; IVF, in-vitro fertilization. a Exposure estimates calculated using the last menstrual period-based pregnancy start date for the purpose of depicting the change in exposure rates according to calendar year and maternal age.
DISCUSSION
Among women undergoing fertility procedures, use of a standard algorithm validated to estimate LMP as the pregnancy start date systematically overestimated the time period during which a fetus could be exposed to a drug in utero, leading to inaccuracy in estimation of the actual start of pregnancy by 16 days on average. This overestimation, combined with the use of letrozole approximately 1 week before conception, resulted in an 8.4-fold overestimation in the rate of pregnancy exposure to letrozole. While we would expect a lesser extent of exposure misclassification for chronic maintenance medications, any drug with abrupt changes in prescribing patterns at onset of pregnancy would be expected to have some degree of exposure misclassification with the LMP-based pregnancy start date.
Using the same algorithm to estimate conception (as LMP + 14 days) had better performance characteristics. This methodology estimated the pregnancy start date, on average, within 2 days of the fertility procedure. However, a 2.3-fold overestimate of letrozole exposure during pregnancy was observed when compared with the fertility procedure-based pregnancy start date. Thus, a safety study of letrozole exposure during pregnancy using the conception-based pregnancy start date might include a sample of congenital malformations with presumed exposure during pregnancy of which more than half had exposure only before conception. When evaluating the risk for congenital malformations, our simulation showed that the misclassification of so many unexposed congenital malformations as exposed could be expected to result in an approximately 50% underestimate in relative risk (e.g., from a true relative risk of 3.0 to an observed relative risk of approximately 1.5). More concerning, a study using the LMP algorithm would be expected to include a sample of congenital malformations exposed to letrozole, of which 88% were exposed only before conception. The resulting observed relative risk is expected to be close to the null. This is an important finding because most drug utilization studies in pregnancy start evaluation for drug exposures at LMP. While exposures between LMP and conception can lead to death of the embryo and failure to establish a pregnancy, they are generally not of concern for teratogenicity (11) , and toxicity prior to conception cannot be studied in a sample of live-birth pregnancies. Of most concern, especially for pregnancy safety studies that assess congenital malformations, is exposure during organogenesis, starting in the third week through the eighth week after conception.
The most concerning pregnancy exposures to letrozole are those during weeks 3-4 (n = 169, 6.0%) after conception when estimating pregnancy start through fertility procedure-based coding. This represents timing of ovulation at the following cycle and might represent inadvertent letrozole exposure in pregnancy. Bleeding during early pregnancy can occur as the fertilized egg implants in the lining of the uterus, which often happens around the timing of the next expected menstrual period. This could lead to misrecognition of pregnancy and another regimen of letrozole treatment (12) . However, some letrozole exposures during this timeframe (weeks 3-4) could also represent natural conception with use of letrozole 1 month after a failed fertility procedure. Women who were diagnosed with infertility might still conceive naturally after a failed IVF or IUI cycle, which would result in attributing letrozole exposure to the wrong cycle and result in a false-positive pregnancy exposure.
Some degree of exposure misclassification might also occur if a letrozole prescription was written and filled immediately following a fertility procedure, with the intent to be used during the next cycle only following a negative pregnancy test. While it is common practice that physicians require a negative pregnancy test before each sequential letrozole prescription (13, 14) , exposures during weeks 1-2 (n = 53, 1.9%) after the fertility procedure might represent this pattern.
Finally, exposure misclassification more than 4 weeks beyond our estimated pregnancy start date could result from some inaccuracy of our algorithm for identification of live-birth deliveries, which has a positive predictive value of 98.2% (15) , or due to failure to record coding for preterm delivery. Preterm births have been reported to have a greater within-week variance in estimation of gestational age than term births (9) . The higher rate of preterm births among women undergoing fertility procedures might drive additional exposure misclassification in the example of letrozole. Because pregnancy testing is highly accurate after 4 weeks of gestation, observed letrozole exposures ≥5 weeks into pregnancy (n = 38, 1.4%) likely represent these types of misclassification and result in an overestimation of the exposure rate during pregnancy.
Prior studies
The LMP-based pregnancy start date was validated among a sample of 225,384 live-birth pregnancies from 8 health plans within the Medication Exposure in Pregnancy Risk Evaluation Program, several of which are Sentinel data partners. It was shown to correctly classify 77.0% of all pregnancies within 2 weeks of the clinical estimate of LMP (9). We found a similar level of accuracy in our study, where the conception-based estimate (LMP + 14 days) occurred within 14 days of the fertility procedure for 78.3% of pregnancies. Achieving higher accuracy is challenging given that even clinical estimates of LMP are expected to identify the timing of conception within approximately 2 weeks. While the algorithm adjusts for coding for preterm and postterm birth, these codes provide gestational age at delivery in 2-week windows. We expect that the length of these windows and the close temporal use of letrozole to the date of conception drives a large portion of the letrozole exposure misclassification observed in our study. Updated International Classification of Diseases, Tenth Revision, Clinical Modification, coding in October 2015 provides gestational age in 1-week windows, which should help to mitigate misclassification when this coding is present.
Another study compared pregnancy exposure data from clinical estimates of LMP in the Kaiser Permanente Colorado Birth Registry with the LMP-based pregnancy start date from claims data. It found minimal misclassification of exposure to longterm maintenance medications during pregnancy, where the prevalence of medication use during pregnancy was within an absolute difference of 1% or less between data sets (15) . However, this study also found a 13.7% difference in the prevalence of exposure to Category X drugs, which are contraindicated during pregnancy, between the LMP-based algorithm and clinical estimates of LMP in the birth registry. These drugs were primarily oral contraceptives. Another study conducted using data from 8 health plans compared medication exposure rates determined with the LMP-based pregnancy start date with those determined using the LMP-based gestational age from birth certificate records (9) . The authors found a high sensitivity and a positive predictive value of ≥95% with the LMP-based pregnancy start, versus birth certificate-based methods, for 2 long-term maintenance medications (both antidepressants). However, the algorithm performance characteristics were lower for 2 shortterm medications (both antibiotics; sensitivity and positive predictive value ≥90%) (9).
Strengths and limitations
We evaluated letrozole exposure using data from a large population where the pregnancy start date could be estimated using the date of a fertility procedure. This unique approach provided a standard against which to validate the performance of our LMP-based and conception-based pregnancy start dates. While we expect IUI procedures to represent the date of conception, determination of conception with IVF procedures must also consider the age of the embryo at implantation (typically 3-5 days) (16) . Although an imperfect estimate of conception for IVF, the fertility procedure date does accurately reflect the timing after which an exposure during pregnancy would be of concern. Furthermore, use of a conception-based pregnancy start date in our study is a novel departure from traditional methodology. It better aligns with the known timing for which a teratogenic substance can lead to congenital malformations, and we demonstrated that it can also lead to substantially reduced exposure misclassification.
Our study was not intended to be generalizable to all pregnancies or all drug exposures. Rather, it provides an illustrative example of the importance of considering the choice of pregnancy start date for drug utilization research in pregnancy. Letrozole was selected due to the high proportion of use immediately prior to conception, and this example is intended to sensitize researchers and clinicians to the ascertainment of pregnancy start date when conducting or reviewing this research. Use of an LMP-based pregnancy start date is expected to result in a greater extent of exposure misclassification for transiently taken medications (e.g., antibiotics or injections) than long-term maintenance medications. Any drug that is subject to an abrupt change in utilization at the onset of pregnancy has potential for exposure misclassification depending on how the pregnancy start date is ascertained.
We also conservatively determined the dates of letrozole exposure, assuming all women took the drug for 5 days after pharmacy dispensing. Receipt of medication in advance of its intended use will bias toward indexing exposures earlier in calendar time than their intended use. This however would bias toward reducing the number of exposed pregnancies and cannot explain the larger number of pregnancies exposed to letrozole with the LMP-based pregnancy start date compared with the conception-based pregnancy start date. Furthermore, women might inadvertently take letrozole on the wrong days of the cycle or stockpile drug supply for use in a subsequent month. Among women receiving letrozole through insurance reimbursement, the typical practice of medicine is to prescribe for only 1 cycle at a time following documentation of a negative pregnancy test (13, 14) , which should limit prescription fills from occurring outside of the 4-week window we assessed.
Finally, when using the fertility procedures to estimate the start of pregnancy, we could not determine what proportion of pregnancy exposures occurring during weeks 3-4 after conception were true inadvertent pregnancy exposures versus natural conception with letrozole 1 month after a failed fertility procedure. The primary focus of our study was to quantify exposure misclassification between different methods for estimating the pregnancy start date, but we did not have access to birth certificates or medical records to obtain more detailed clinical information on the start of pregnancy.
Conclusion
Study investigators evaluating drug utilization during pregnancy should consider estimates of conception (LMP + 14 days) as an alternative to LMP to estimate the pregnancy start date, particularly for short-duration exposures proximal to conception. Improving estimates of conception dates will facilitate narrowing the timing of exposure to the risk window of organogenesis in the first trimester of pregnancy. A more accurate determination of the pregnancy start date would reduce misclassification in studies that assess drug safety in pregnancy and result in improved validity of study findings. To further improve the prediction accuracy of algorithms to identify the start of pregnancy, coding for fertility procedures should be incorporated when available. 
